A phase 3 pivotal study of Resiniferatoxin in osteoarthritis knee pain
Latest Information Update: 27 Sep 2022
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Pain
- Focus Registrational; Therapeutic Use
- Sponsors Sorrento Therapeutics
- 26 Sep 2022 According to an Sorrento Therapeutics media release, the company plans to conduct the trial in the first half of 2023.
- 19 Jun 2019 According to an Sorrento Therapeutics media release, this study is in advanced planning, with an anticipated first patient enrollment target date in early 2020.
- 28 Jan 2019 New trial record